126 related articles for article (PubMed ID: 10924734)
1. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group.
Arosio M; Sartore G; Rossi CM; Casati G; Faglia G; Manzato E
Atherosclerosis; 2000 Aug; 151(2):551-7. PubMed ID: 10924734
[TBL] [Abstract][Full Text] [Related]
2. Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly.
Tan KC; Pang RW; Tiu SC; Lam KS
Clin Endocrinol (Oxf); 2003 Nov; 59(5):558-64. PubMed ID: 14616878
[TBL] [Abstract][Full Text] [Related]
3. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I.
Wildbrett J; Hanefeld M; Fücker K; Pinzer T; Bergmann S; Siegert G; Breidert M
Exp Clin Endocrinol Diabetes; 1997; 105(6):331-5. PubMed ID: 9439928
[TBL] [Abstract][Full Text] [Related]
4. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
5. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
6. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.
Tan KC; Shiu SW; Janus ED; Lam KS
Atherosclerosis; 1997 Feb; 129(1):59-65. PubMed ID: 9069518
[TBL] [Abstract][Full Text] [Related]
7. Lipid and lipoprotein factors associated with variation in Lp(a) density.
Rainwater DL; Ludwig MJ; Haffner SM; VandeBerg JL
Arterioscler Thromb Vasc Biol; 1995 Mar; 15(3):313-9. PubMed ID: 7749840
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.
Delaroudis SP; Efstathiadou ZA; Koukoulis GN; Kita MD; Farmakiotis D; Dara OG; Goulis DG; Makedou A; Makris P; Slavakis A; Avramides AI
Clin Endocrinol (Oxf); 2008 Aug; 69(2):279-84. PubMed ID: 18194486
[TBL] [Abstract][Full Text] [Related]
9. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
[TBL] [Abstract][Full Text] [Related]
10. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly.
Maldonado Castro GF; Escobar-Morreale HF; Ortega H; Gómez-Coronado D; Balsa Barro JA; Varela C; Lasunción MA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):313-9. PubMed ID: 10971448
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
12. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
13. A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men.
Svensson J; Bengtsson BA; Taskinen MR; Wiklund O; Johannsson G
Growth Horm IGF Res; 2000 Jun; 10(3):118-26. PubMed ID: 10942632
[TBL] [Abstract][Full Text] [Related]
14. Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins.
Beentjes JA; van Tol A; Sluiter WJ; Dullaart RP
Atherosclerosis; 2000 Dec; 153(2):491-8. PubMed ID: 11164439
[TBL] [Abstract][Full Text] [Related]
15. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a).
Klausen IC; Nielsen FE; Hegedüs L; Gerdes LU; Charles P; Faergeman O
Metabolism; 1992 Aug; 41(8):911-4. PubMed ID: 1386404
[TBL] [Abstract][Full Text] [Related]
17. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
18. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men.
Hislop MS; St Clair Gibson A; Lambert MI; Noakes TD; Marais AD
Atherosclerosis; 2001 Dec; 159(2):425-32. PubMed ID: 11730823
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
[TBL] [Abstract][Full Text] [Related]
20. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
